ToeFX Light Therapy for Chronic Venous Leg Ulcers
Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study
Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.
A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.
The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.
This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.
The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.
A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.
ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.
This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Ahmed Kayssi, MD MSc FRCSC
- 전화번호: (416) 691-2030
- 이메일: ahmed.kayssi@sunnybrook.ca
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M4L 3Y3
- East Toronto Vascular Clinic
-
연락하다:
- Ahmed Kayssi, MD MSc FRCSC
- 전화번호: (416) 691-2030
- 이메일: ahmed.kayssi@sunnybrook.ca
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Age 18 years or older
- Able to attend weekly visits for up to 12 weeks
- Chronic venous leg ulcer (CEAP C6) of the lower extremity
- Ulcer duration of 4 weeks or more
- Ulcer size between 1 cm² and 20 cm² at baseline
- Receiving standard-of-care compression therapy, or eligible to initiate it
- Able to provide informed consent and comply with study procedures
Exclusion Criteria:
- Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
- Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
- Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
- Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
- Heavy exudate requiring negative-pressure wound therapy
- Known photosensitivity or allergy to methylene blue or light-based therapies
- Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
- Pregnancy or lactation
- Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
- Participation in another interventional study within 30 days of screening
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 장치 타당성
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: ToeFX Treatment
Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure |
Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment adherence
기간: Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions |
Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
|
Safety: Adverse Events
기간: Baseline through Healing Confirmation Visit (up to 14 weeks)
|
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs |
Baseline through Healing Confirmation Visit (up to 14 weeks)
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percent Change in Wound Area From Baseline
기간: Baseline, week 4, week 8, and week 12
|
Percent change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
|
Complete wound epithelialization
기간: 12 weeks
|
Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician |
12 weeks
|
|
Time to complete wound healing
기간: 12 weeks
|
Time (days) from baseline to complete epithelialization |
12 weeks
|
|
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
기간: Baseline to 12 weeks/ end of treatment
|
Change in wound bed characteristics measured using the BWAT |
Baseline to 12 weeks/ end of treatment
|
|
Change in pain score
기간: Baseline to 12 weeks/ end of treatment
|
Change in pain score (0-10 Numeric Rating Scale) |
Baseline to 12 weeks/ end of treatment
|
|
Change in health-related quality of life
기간: 12 weeks/ end of treatment
|
Change in EQ-5D-5L score |
12 weeks/ end of treatment
|
|
Patient satisfaction
기간: 12 weeks/ end of treatment
|
Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire |
12 weeks/ end of treatment
|
|
Clinician feasibility
기간: 14 weeks or earlier if wound healing
|
Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow |
14 weeks or earlier if wound healing
|
|
Absolute Change in Wound Area From Baseline
기간: Baseline, week 4, week 8, and week 12
|
Absolute change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
공동 작업자 및 조사자
수사관
수사관
- 수석 연구원: Ahmed Kayssi, MD MSc FRCSC, East Toronto Vascular Clinic
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- PRO04244160_ToeFX
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .